Clik here to view.
Researchers develop nanodevice to deliver immunotherapy
Image credit: Houston Methodist Researchers at Houston Methodist Research Institute have created a nanodevice that can be used to deliver immunotherapy to treat triple-negative breast cancer. The tiny...
View ArticleClik here to view.
Delcath registers $100m offering
Delcath Systems (NSDQ:DCTH) registered a $100 million offering with the SEC this week to support the development of its system designed to administer high-dose chemotherapy to the liver. The company’s...
View ArticleClik here to view.
Inovio touts intradermal delivery of HIV vaccine
Inovio Pharmaceuticals (NSDQ:INO) reported today that its synthetic HIV vaccine, Pennvax-GP, demonstrated durable antibody and T cell immune responses throughout a Phase I trial. The company found that...
View ArticleClik here to view.
The top 10 medical disruptors of 2019
[Image from unsplash.com]The Cleveland Clinic for the past 16 years has predicted what the top 10 medical disruptors will be for the following year. The health provider seeks input from 150 to 200 of...
View ArticleClik here to view.
GenSight Biologics launches trial for gene therapy, eye device combo
GenSight Biologics (EPA:SIGHT) said today that the first person was treated in a first-in-man trial evaluating GenSight’s gene therapy candidate, GS030-DP, in combination with a wearable optronic...
View ArticleClik here to view.
Genentech touts data for refillable eye implant in wet-AMD trial
Roche‘s (OTC:RHHBY) Genentech touted additional positive data last week from a Phase II study of its Port Delivery System, a refillable eye implant designed to deliver ranibizumab to treat wet...
View ArticleClik here to view.
Clearside Biomedical reports analyses from pivotal trial of eye drug
Clearside Biomedical (NSDQ:CLSD) touted new analyses of data from the company’s Phase III pivotal trial of suprachoroidal CLS-TA in people with uveitic macular edema. The company’s investigational...
View ArticleClik here to view.
Sanofi leads $50m round for Enable Injections’ on-body drug-delivery platform
Enable Injections said last week that it closed a $50 million Series B round, led by Sanofi (NYSE:SNY), to fund the development of its enFuse on-body drug-delivery system. Previous investors, including...
View ArticleClik here to view.
Carrot raises $25m for tech-enabled smoking cessation program
Digital health company Carrot said today that it raised $25 million to commercialize its tech-enabled Pivot smoking cessation program. The round was led by Johnson & Johnson‘s (NYSE:JNJ) strategic...
View ArticleClik here to view.
Philips-Medisize launches third-gen Connected Health Platform
Phillips-Medisize said today it completed the roll-out of its third-gen Connected Health Platform, a cloud-based data system for pharmaceutical and drug delivery device developers. The newly launched...
View ArticleClik here to view.
KemPharm inks Apadaz licensing deal with KVK Tech
KemPharm (NSDQ:KMPH) said yesterday it inked a collaborative licensing deal with KVK Tech to obtain U.S. commercial rights to the company’s FDA-approved Apadaz drug. Through the agreement, KemPharm is...
View ArticleClik here to view.
Reva launches Fantom Encore bioresorbable scaffold
Reva Medical (ASX:RVA) said this week that it launched its Fantom Encore bioresorbable, drug-eluting scaffold and that the first person was treated in a post-market trial of the device. The Fantom...
View ArticleClik here to view.
Abbott wins FDA nod for FreeStyle Libre’s mobile app
Abbott (NYSE:ABT) said today that it won FDA approval for a mobile app that is designed for the company’s FreeStyle Libre continuous glucose monitoring system. The FreeStyle LibreLink app allows users...
View ArticleClik here to view.
FDA clears 23andMe for pharmacogenetics testing
The FDA recently cleared a pharmacogenetic DNA test from 23andMe that is designed to determine how users will react to certain pharmaceutical drugs. The FDA cleared the new 23andMe test to give...
View ArticleClik here to view.
New diabetes software from Klue features mealtime insulin reminders
Digital health company Klue announced this week that its latest AI-driven software is a module designed for people with Type I diabetes. The technology features autonomous meal detection capabilities...
View ArticleClik here to view.
FDA issues Class I recall for Roche Diagnostics’ warfarin test strips
The FDA today issued a Class I recall for certain lots of Roche Diagnostics‘ warfarin test strips used with the CoaguCheck test meter devices. Roche voluntarily recalled the strips in September,...
View ArticleClik here to view.
Aquestive wins FDA nod for seizure oral film
Shares in Aquestive Therapeutics (NSDQ:AQST) rose today after the company announced FDA approval for its Sympazan oral film for the adjunctive treatment of seizures associated with Lennox-Gastaut...
View ArticleClik here to view.
FDA to develop new framework for opioid analgesics following AcelRx approval
The FDA last week approved AcelRx‘s (NSDQ:ACRX) Dsuvia sufentanil product, noting that use of the opioid will be tightly restricted to adults experiencing acute pain in medically-supervised healthcare...
View ArticleClik here to view.
Medherant touts results for ibuprofen transdermal patch
Medherant said today that it successfully finished two Phase I studies with its ibuprofen transdermal drug-delivery patch. According to the UK-based company, the Tepi patch was well tolerated by the...
View ArticleClik here to view.
Intersect ENT tops estimates with Q3 results
Shares in Intersect ENT (NSDQ:XENT) fell today even though the medical device maker topped expectations on Wall Street with its third-quarter financial results. The Menlo Park, Calif.-based company...
View Article